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Purpose: To determine the role of vascular endothelial growth factor (VEGF) in macular edema 
secondary to branch retinal vein occlusion (BRVO).
Patients and methods: Aqueous humor samples were collected from 52 eyes with macular 
edema secondary to BRVO before intravitreal drug injections and from 62 control eyes with 
cataract. VEGF was measured using an enzyme-linked immunosorbent assay. Fluorescein 
angiography showed capillary nonperfused areas (NPAs). Macular edema was evaluated by 
optical coherence tomography as the central retinal thickness.
Results: The mean aqueous VEGF levels in eyes with BRVO and control eyes with cataract 
were, respectively, 290.5 pg/mL ± 294.9 pg/mL (range 81.9 pg/mL−1567.3 pg/mL) and 
118.0 pg/mL ± 50.1 pg/mL (range 24.6 pg/mL−241.1 pg/mL), which differed significantly 
(P , 0.0001). The mean VEGF level in eyes with BRVO without apparent NPA was 
171.4 pg/mL ± 52.5 pg/mL (range 90.9 pg/mL−299.9 pg/mL), which was significantly higher than 
controls (P = 0.001). VEGF levels were correlated positively with the size of NPA (P = 0.0002) 
but not with the central retinal thickness.
Conclusion: The aqueous VEGF concentration in patients with macular edema secondary to 
BRVO increased significantly and was correlated significantly with the size of NPA. Aqueous 
VEGF increased even in eyes without apparent NPA.
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Introduction
Branch retinal vein occlusion (BRVO), a common retinal vascular disease, is often 
associated with macular edema, which is the most frequent cause of visual impairment 
in these patients.1,2 Thus, it is critical to determine the cellular and molecular factors that 
underlie the pathogenesis of macular edema secondary to BRVO. Intraocular levels of 
cytokines, such as vascular endothelial growth factor (VEGF) and interleukin (IL)-6, 
have been reported to increase in retinal vein occlusion.3–5
VEGF produced in the retina may play a key role in the pathogenesis of macular 
edema secondary to BRVO, similar to other retinal vascular diseases, such as proliferative 
diabetic retinopathy and retinopathy of prematurity.3 VEGF causes a marked increase 
in vascular permeability by provoking conformational changes in the tight junctions of 
the retinal vascular endothelial cell.6–8 Intravitreal injection of bevacizumab (Avastin; 
Genentech, San Francisco, CA, USA), a full-length humanized monoclonal antibody 
that binds and inhibits all biologically active forms of VEGF,9 is effective for treating 
macular edema secondary to retinal vein occlusion.10,11 These findings suggest that VEGF 
may contribute to the development of macular edema secondary to BRVO.
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Noma et al reported that VEGF levels increased in the 
vitreous fluid with macular edema associated with BRVO 
and were correlated positively with both the size of the 
nonperfused area (NPA) and the retinal thickness resulting 
from macular edema.12–14 However, these reports included 
eyes that had been treated previously with photocoagulation 
therapy, which may have affected the VEGF concentration, 
making an understanding of the pathogenesis difficult. 
Furthermore, the VEGF levels in eyes with BRVO without 
an NPA are poorly understood. Therefore, we measured the 
VEGF concentrations in the aqueous humor in a large number 
of treatment-naive patients with macular edema secondary 
to BRVO with or without NPA and investigated the relation 
between aqueous VEGF levels and the clinical conditions 
of BRVO.
Materials and methods
We prospectively measured the VEGF concentrations in the 
aqueous humor of 52 eyes of 52 patients (29 women, 23 men) 
with macular edema secondary to BRVO. The mean patient 
age was 68.0 years ± 10.0 years (range 39 years–90 years).
The inclusion criteria were treatment-naive BRVO 
in eyes that had not undergone any previous treatments, 
including photocoagulation therapy, sub-Tenon’s injection 
of triamcinolone acetonide or intravitreal injection of 
steroids, tissue plasminogen activator, or anti-VEGF drugs; 
central retinal thickness (CRT) exceeding 300 µm; best-
corrected visual acuity (BCVA) of 0.5 or worse measured 
with the Landolt C chart; no diabetes mellitus; and no 
thick hemorrhages that obscured fundus visualization. 
For statistical analysis, the BCVA values were converted 
to the logarithm of the minimum angle of resolution 
(logMAR).
We also obtained aqueous humor from 62 eyes of 62 age-
adjusted control patients (39 women, 23 men; mean age 
70.9 years ± 9.3 years; range 44 years–82 years) with cataract 
alone. None of the 62 patients had diabetes mellitus.
Aqueous humor samples were collected from the BRVO 
group immediately before intravitreal injection of either 
triamcinolone acetonide or bevacizumab and from the control 
group just before cataract surgery.
All intravitreal injections were administered, and samples 
were collected using a standard sterilization procedure that 
included instillation of topical povidone-iodine and antibiotic 
drops. All samples were stored in a deep freezer at −80°C 
until analysis. The VEGF concentrations were measured 
using an enzyme-linked immunosorbent assay (ELISA) for 
human VEGF (Human VEGF Quantikine ELISA Kit; R&D 
Systems, Minneapolis, MN, USA); the primary antibody 
targeted two VEGF isoforms: VEGF
121
 and VEGF
165
. The 
lowest detectable limit of VEGF concentration was 9 pg/mL, 
according to the manufacturer’s instructions.
Fluorescein angiography (FA) was performed to detect 
the NPAs before treatment. The sizes of the NPAs were 
analyzed with Scion Image software (Scion, Frederick, MD, 
USA) and expressed in disc areas (DAs). We divided the 
BRVO group into two subgroups for further analysis based 
on the presence (+) or absence (−) of a NPA. The NPA+ group 
included eyes with an NPA observed on FA, and the NPA− 
group included eyes without apparent NPA on FA. Optical 
coherence tomography (OCT) was performed using Stratus 
OCT (Carl Zeiss Meditec, Dublin, CA, USA), and the CRT 
was analyzed using the fast macular thickness-scan pattern 
protocol that averages the retinal thickness within 1 mm in 
diameter over the central fovea. Existence of subretinal fluid 
(SRF) was also analyzed by OCT. Sample data were analyzed 
using GraphPad Prism 6 software (GraphPad Software, 
La Jolla, CA, USA).
Unpaired t-test was used to compare the two independent 
groups with normal distribution. The Mann–Whitney test 
was used to compare the two independent groups without 
normal distribution. Spearman’s r correlation test was used 
to analyze the correlation between the VEGF concentrations 
and the CRT and the size of the NPA in eyes with BRVO. 
P , 0.05 was considered significant.
The institutional review board of Shiga University 
of Medical Science Hospital approved this study, which 
followed the principles of the Declaration of Helsinki. All 
participants provided written informed consent before the 
start of the study.
Results
Based on the presence of an NPA on FA, 52 eyes with BRVO 
were divided into two subgroups: NPA+ (39 eyes, 75.0%) and 
NPA− (13 eyes, 25.0%).
In the 52 eyes with BRVO, the mean logMAR BCVA 
was 0.610 ± 0.262 (range 0.301–1.398). The mean CRT was 
557.3 µm ± 175.5 µm (range 205 μm–109 μm). SRF was 
detected in 22 (42.3%) of 52 eyes with BRVO. The mean 
period between the onset of BRVO and sample collec-
tion was 5.0 months ± 4.6 months (range 0 DAs−171.3 
DAs). The mean size of NPA was 32.2 DAs ± 38.2 DAs 
(range 0 DAs−171.3 DAs).
The mean aqueous VEGF concentrations in the eyes 
with BRVO were 290.5 pg/mL ± 294.9 pg/mL (range 
81.9 pg/mL−1567.3 pg/mL) and 118.0 pg/mL ± 50.1 pg/mL 
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(24.6 pg/mL−241.1 pg/mL) in the control group. The mean 
VEGF concentration was significantly higher in eyes with 
BRVO than in the control cataract eyes (P , 0.0001 by 
Mann–Whitney test). The mean aqueous VEGF concentration 
in the NPA− group was 171.4 pg/mL ± 52.5 pg/mL 
(90.9 pg/mL−299.9 pg/mL), which was significantly higher 
than in the control cataract eyes (P = 0.0009 by 
unpaired t-test). The aqueous VEGF concentration was 
330.2 pg/mL ± 330.7 pg/mL (81.9 pg/mL−1567.3 pg/mL) 
in the NPA+ group, which was also significantly higher than 
in the control cataract eyes (P , 0.0001 by Mann–Whitney 
test) (Figure 1). The mean aqueous VEGF concentration in 
the NPA+ group was higher than in the NPA− group; however, 
the difference did not reach significance (P = 0.0852 by 
Mann–Whitney test) (Table 1).
In BRVO eyes with SRF (n = 22), the mean aqueous 
VEGF concentration, the size of NPA, and the CRT were 
220.5 pg/mL ± 90.3 pg/mL, 36.9 DAs ± 39.5 DAs, and 
631.5 µm ± 199.9 µm, respectively. In BRVO eyes without 
SRF (n = 30), they were 341.8 pg/mL ± 374.9 pg/mL, 28.7 
DAs ± 37.5 DAs, and 502.9 µm ± 134.2 µm, respectively. 
Statistical significance was found in CRT (P = 0.0077 by 
unpaired t-test), but not in the aqueous VEGF concentration 
(P = 0.9483 by Mann–Whitney test) and the NPA (P = 0.201 
by Mann–Whitney test).
In all 52 eyes with BRVO, the size of the NPA was 
positively significantly correlated with the aqueous VEGF 
concentration (Spearman’s r = 0.488, P = 0.0002) (Figure 2). 
However, no correlation was found between the aqueous 
VEGF concentration and the CRT (Spearman’s r = 0.186, 
P = 0.187) (Figure 3).
Discussion
Macular edema secondary to BRVO is a frequent cause of 
visual impairment. However, no effective treatment has 
been established, although various treatments have been 
attempted.11,15–18 To determine an effective treatment, the 
pathogenesis of the macular edema secondary to BRVO 
must be determined. VEGF is a primary cytokine that 
contributes to the development of macular edema. VEGF 
expression is promoted by hypoxia, and causes changes in 
the conformational structure of the tight junctions of the 
retinal vascular endothelial cells and induces increased 
vascular permeability.6–8 The aqueous and vitreous VEGF 
levels increase in eyes with proliferative diabetic retinopa-
thy, diabetic macular edema, central retinal vein occlusion, 
and BRVO.3,12–14
Noma et al reported that the aqueous VEGF level in 
19 eyes with macular edema associated with BRVO was 
351 pg/mL ± 273 pg/mL, which was significantly higher 
compared with the control group. They included nine patients 
who had undergone previous photocoagulation therapy 
before sample collection.12 The previous treatment might 
have affected the production of VEGF in BRVO eyes.3 
Therefore, the current study included 52 treatment-naive 
eyes with BRVO with macular edema alone. The aqueous 
VEGF concentration in eyes with macular edema secondary 
to treatment-naive BRVO was 290.5 pg/mL ± 294.9 pg/mL, 
which was significantly higher than in the control eyes 
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Figure 1 Aqueous VEGF levels of all BRVO eyes (NPA+/−), NPA+ group, and NPA− 
group were significantly higher than the control cataract group.
Note: ****P , 0.0001; ***P = 0.0009; dashed lines stand for mean.
Abbreviations: BRVO, branch retinal vein occlusion; NPA, nonperfused area; 
VEGF, vascular endothelial growth factor.
Table 1 Demographic data in BRVO subgroup
NPA+ (n = 39) NPA– (n = 13) P
Mean ± SD Range Mean ± SD Range
Age (years)  67.3 ± 10.5 39–90  70.3 ± 8.3 58–88 0.3449a
Interval* (months)  4.6 ± 4.1 0.7–18.0  5.9 ± 5.5 0.8–17.3 0.5762b
LogMAR VA 0.642 ± 0.271 0.301–1.398 0.513 ± 0.214 0.301–1.000 0.125a
CRT (µm) 601.4 ± 177.7 205–1095 424.9 ± 75.2 319–576 0.0011a
NPA (DA)  42.9 ± 38.5 4.1–171.3 0 – ,0.0001b
VEGF (pg/mL) 330.2 ± 330.7 81.9–1567.3 171.4 ± 52.5 90.9–299.9 0.0852b
Notes: *Interval between onset of BRVO and sample collection; aunpaired t-test, bMann–Whitney test.
Abbreviations: BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; LogMAR VA, logarithm of minimum angle of 
resolution – visual acuity; NPA, nonperfused area; SD, standard deviation; VEGF, vascular endothelial growth factor.
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with cataract. We confirmed that the VEGF concentration 
was elevated in treatment-naive eyes with macular edema 
secondary to BRVO, which was similar to the results reported 
by Noma et al,12 which included eyes with a history of 
photocoagulation therapy.
It has been reported that ischemic BRVO tends to occur in 
serous retinal detachment.19 Therefore, we selected 13 of 52 eyes 
with BRVO without apparent NPA seen on FA. Even in eyes 
without NPA, the aqueous VEGF concentration was 171.4 pg/
mL ± 52.5 pg/mL, which was significantly higher than the 
control group, suggesting that the presence of microischemic 
lesion undetectable by FA might be responsible for increased 
VEGF concentrations. The difference in the aqueous VEGF 
concentration between the NPA+ and NPA− groups did not 
reach significance, probably because of the small number of 
patients. Noma et al also reported that the aqueous VEGF 
level was significantly positively correlated both with the 
size of the NPA and the CRT in BRVO.12 We also found a 
significant positive correlation between the aqueous VEGF 
concentration and the size of the NPA. However, no correlation 
was found between the aqueous VEGF concentration and the 
CRT, although we had a greater number of patients. There is 
no previous report about this issue.
The reason could be the varying locations of the NPA in 
BRVO. Retinal vein occlusion develops at various sites and 
in areas of different sizes. Even when the NPA is relatively 
large, the foveal function could be affected less if the involved 
location is not near the macula. A second reason could be the 
localized effect of VEGF in BRVO. Sawada et al, who reported 
that the aqueous VEGF concentration in 21 eyes with myopic 
choroidal neovascularization was lower than in controls, 
speculated that the VEGF might be localized and cause 
choroidal neovascularization.20 Similarly, VEGF secreted from 
NPA distant from the macula might have little effect on the 
macula. Another reason could be the existence of SRF caused 
by other vascular permeability factors. We found that the CRT 
was significantly greater in BRVO eyes with SRF than without 
SRF, but the aqueous VEGF concentration and NPA was not 
different between them. This suggests that cytokines other than 
VEGF may be involved in BRVO. Indeed, it has been reported 
that inflammatory cytokines, such as IL-6, IL-8, and monocyte 
chemoattractant protein 1 may contribute to the pathogenesis 
of macular edema with BRVO, even in nonischemic BRVO.21 
Therefore, inflammation could also elevate the VEGF level 
along with inflammatory cytokines.
Conclusion
The aqueous VEGF concentration in treatment-naive 
eyes with macular edema secondary to BRVO increased 
significantly and was correlated with the size of the NPA. 
The aqueous VEGF concentration significantly increased 
even in BRVO eyes without apparent NPA, suggesting that 
micro-disperfusion and/or inflammatory change may increase 
VEGF. The location and size of the NPA and the effect of 
locally secreted VEGF also seem to be important, because 
the VEGF was not correlated with the CRT.
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